August 05, 2025

Periodontal Disease: Systemic Associations Across Multiple Organ Systems

Evidence links periodontal inflammation to systemic dysfunction across cardiovascular, endocrine, renal, respiratory, and neurologic systems.

Conexiant

July 30, 2025

Mortality Among Surgeons in the United States 

National mortality data reveal that surgeons face higher death rates than non-surgeon physicians, with cancer and external causes contributing prominently.

Conexiant

July 31, 2025

Triple Cardiovascular Therapy Linked With Slower Cognitive Decline

Combination use of antihypertensive, lipid-lowering, and antidiabetic agents shows associations with cognitive preservation and postmortem neuropathologic changes in aging cohorts.

Conexiant

July 25, 2025

Pregnancy Not Tied to Higher Stroke Risk

A study evaluates pregnancy as a potential modifier of long-term neurologic and vascular outcomes in women with prior cervical artery dissection.

Conexiant

July 23, 2025

Are Wearables Mining the Mind?

As neurotech devices move from clinics to consumers, states are racing to safeguard brainwave data from earbuds, sleep trackers, and AI-powered apps—raising new questions about privacy, consent, and medical ethics.

KFF Health News

July 17, 2025

Semaglutide, Tirzepatide Linked to Lower Dementia Risk

Researchers found that semaglutide and tirzepatide were associated with reduced risks of dementia, stroke, and all-cause mortality in patients with type 2 diabetes and obesity.

Conexiant

July 09, 2025

Better Cholesterol Treatment Could Prevent Thousands of Cardiovascular Events

Most adults with high LDL cholesterol are not receiving recommended treatments and are not fully following clinical guidelines.

Conexiant

July 10, 2025

No Heart Risk Found With Triptan Use

A large real-world study found no significant increase in short-term heart attack or stroke risk among migraine patients using triptans, including those with cardiovascular risk factors.

Conexiant

July 09, 2025

PP-007: A First-in-Class Neuroprotective Agent Moves into Phase 3 Stroke Trial

A novel investigational compound, PP-007 (PEGylated carboxyhemoglobin), is advancing to a global Phase 3 clinical trial as a potential breakthrough in the treatment of acute ischemic stroke

Baptist Health South Florida